UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

Clinical cancer research, 2006-12, Vol.12 (23), p.7046-7053

2006

Volltextzugriff (PDF)

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer

Clinical breast cancer, 2018-02, Vol.18 (1), p.e89-e95

2018

Volltextzugriff (PDF)

Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study

Clinical cancer research, 2004-09, Vol.10 (18), p.6101-6110

2004

Volltextzugriff (PDF)

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia

Blood, 2005-11, Vol.106 (10), p.3380-3382

2005

Volltextzugriff (PDF)

Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma

Cancer research (Chicago, Ill.), 2003-03, Vol.63 (5), p.965-971

2003

Volltextzugriff (PDF)

Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8835-8844

2005

Volltextzugriff (PDF)

IFN-γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice

Blood, 2005-02, Vol.105 (4), p.1558-1565

2005

Volltextzugriff (PDF)

Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

Clinical cancer research, 2003-12, Vol.9 (16 Pt 1), p.5810-5812

2003

Volltextzugriff (PDF)

Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+T-cell restoration

Blood, 2002-10, Vol.100 (7), p.2341-2348

2002

Volltextzugriff (PDF)

Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder

JNCI : Journal of the National Cancer Institute, 2004-10, Vol.96 (19), p.1447-1457

2004

Volltextzugriff (PDF)

Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator

Genes & development, 1995-06, Vol.9 (11), p.1377-1387

1995

Volltextzugriff (PDF)

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

Clinical cancer research, 2004-09, Vol.10 (18), p.6101-6110

2004

Volltextzugriff (PDF)

Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1

Genes & development, 1996-09, Vol.10 (18), p.2335-2347

1996

Volltextzugriff (PDF)

PU.1 is a Component of a Multiprotein Complex Which Binds an Essential Site in the Murine Immunoglobulin λ2-4 Enhancer

Molecular and cellular biology, 1993-10, Vol.13 (10), p.6452-6461

1993

Volltextzugriff (PDF)

GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder

The Journal of clinical investigation, 2001-09, Vol.108 (6), p.887-894

2001

Volltextzugriff (PDF)

Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism

Blood, 2004-11, Vol.104 (11), p.2507-2507

2004

Volltextzugriff (PDF)

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia

Blood, 2005-11, Vol.106 (10), p.3380

2005

Volltextzugriff (PDF)

A phase 2 study of rituximab in combination with recombinant lnterleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

Clinical cancer research, 2006, Vol.12 (23), p.7046-7053

2006

Volltextzugriff (PDF)

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma

Blood, 2005-11, Vol.106 (11), p.944-944

2005

Volltextzugriff (PDF)

Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma

Blood, 2005-11, Vol.106 (11), p.2407-2407

2005

Volltextzugriff (PDF)

A pair of interacting transcription factors implicated in immunoglobulin lambda enhancer function

Eisenbeis, Charles Fredrick

1994

Volltextzugriff (PDF)

OCEANS: Optimizing compilers for embedded applications

Euro-Par'97 Parallel Processing, 2005, Vol.1300, p.1351-1356

2005

Volltextzugriff (PDF)

OCEANS - Optimising Compilers for Embedded Applications

Euro-Par'99 Parallel Processing, 1999, p.1171-1175

1999

Volltextzugriff (PDF)

OCEANS: Optimising compilers for embedded applicatioNS

Euro-Par’98 Parallel Processing, 1998, p.1123-1130

1998

Volltextzugriff (PDF)

The Controversy Over Executive Compensation

Journal of Applied Corporate Finance, 2004-01, Vol.16 (1), p.108-111

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer

Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia

Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma

Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12

IFN-γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice

Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+T-cell restoration

Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder

Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1

PU.1 is a Component of a Multiprotein Complex Which Binds an Essential Site in the Murine Immunoglobulin λ2-4 Enhancer

GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder

Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia

A phase 2 study of rituximab in combination with recombinant lnterleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma

Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma

A pair of interacting transcription factors implicated in immunoglobulin lambda enhancer function

OCEANS: Optimizing compilers for embedded applications

OCEANS - Optimising Compilers for Embedded Applications

OCEANS: Optimising compilers for embedded applicatioNS

The Controversy Over Executive Compensation

Suchergebnisse filtern